Health

The rising popularity of weight-loss medications like Ozempic and Wegovy has prompted increased scrutiny of their key ingredient, semaglutide, and its broader impact on healthcare systems. Prescriptions for these drugs have seen a significant increase in recent years, fueled by both legitimate medical use and off-label demand, raising questions about accessibility, affordability, and potential long-term effects.

These medications, belonging to a class of drugs known as GLP-1 receptor agonists, were initially developed to treat type 2 diabetes. They work by mimicking a natural hormone that regulates appetite and blood sugar levels, leading to weight loss as a secondary effect. While Ozempic is currently only approved for diabetes treatment in Australia, it is marketed under the brand name Wegovy overseas specifically for weight management, leading some Australians to seek prescriptions “off label” or source the medication from compounding pharmacies.

The increasing demand has created shortages, impacting patients who rely on these medications for diabetes management. The Therapeutic Goods Administration (TGA) has acknowledged these shortages and is attempting to manage the situation by asking doctors and pharmacies to prioritize prescriptions for those with type 2 diabetes, but it lacks the authority to prevent doctors from prescribing Ozempic for weight loss based on their clinical judgment. These shortages are expected to last until 2025, according to the TGA.

Wegovy Access Expanding in Australia

Australia is taking steps to improve access to Wegovy, specifically for individuals with severe obesity and established cardiovascular disease. As of January 12, 2026, the government announced plans to subsidize Wegovy through the Pharmaceutical Benefits Scheme (PBS) for patients with a Body Mass Index (BMI) of 35 or higher who have experienced a cardiovascular event, such as a heart attack or stroke. This move aims to address health inequities, as currently over 400,000 Australians are paying between $4,000 and $5,000 annually for GLP-1 medications. The change is expected to result in a “very substantial bill for taxpayers,” according to Health Minister Mark Butler, though the exact cost remains unclear.

The PBS listing will too introduce a maximum price cap for all drugs on the subsidy scheme, with prescriptions costing a maximum of $25, and $7.70 for pensioners and concession card holders. This represents a significant reduction in cost for eligible patients.

Semaglutide: How it Works and Potential Risks

Semaglutide, the active ingredient in both Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) medication. It functions by suppressing appetite, leading to reduced food intake and subsequent weight loss. Both drugs are manufactured by Novo Nordisk. While effective, these medications are not without potential side effects. On December 1, 2025, Australia’s medicine regulator issued a warning about a potential link between Ozempic and Wegovy and suicidal ideation.

The potential benefits extend beyond weight loss, with some research suggesting GLP-1 medications may offer additional health advantages. Yet, Health Minister Butler emphasized that these drugs are “extraordinary” and require careful consideration.

The Broader Implications

The increased use of these medications raises broader questions about the societal approach to obesity and weight management. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended Wegovy’s addition to the PBS in late 2025, recognizing the potential benefits for a specific population. However, the long-term effects of widespread GLP-1 agonist use remain to be fully understood.

As the PBS listing of Wegovy moves forward, negotiations between the government and Novo Nordisk will be crucial in determining the final cost and accessibility of the medication. The situation highlights the complex interplay between pharmaceutical innovation, public health policy, and the economic realities of healthcare.

Disclaimer: This article provides informational content and should not be considered medical advice. Consult with a qualified healthcare professional for personalized guidance on weight management and medication options.

What are your thoughts on the increasing use of weight-loss medications? Share your perspective in the comments below.

Children born prematurely face a significantly elevated risk of neurodevelopmental disabilities, extending well into school age, according to recent research. A study following children born preterm found a higher prevalence of conditions like cerebral palsy and learning difficulties at age 12 compared to those born at full term. This underscores the long-term impact of preterm birth and the critical need for ongoing monitoring and support for these children as they navigate developmental milestones.

The findings, which examined a cohort of children born prematurely, highlight the lasting effects of early birth on cognitive and motor skills. While advancements in neonatal care have dramatically improved survival rates for preterm infants, the study emphasizes that survival is only the first step. Addressing the potential for long-term disabilities requires a comprehensive approach, beginning in the neonatal intensive care unit and continuing through childhood and adolescence. The focus is shifting towards not just saving babies, but ensuring they thrive.

Increased Risk of Neurodevelopmental Challenges

The research revealed that children born preterm were more likely to experience a range of neurodevelopmental challenges at age 12. These included difficulties with academic performance, attention deficits, and impairments in motor coordination. Specifically, the study noted a higher incidence of cerebral palsy, a group of disorders affecting movement and posture, among children born prematurely. Preterm birth, defined as birth before 37 weeks of gestation, can disrupt critical brain development, leading to these long-term consequences. According to the Centers for Disease Control and Prevention (CDC), in 2022, preterm birth affected about 1 of every 10 infants born in the United States .

Factors Contributing to Long-Term Outcomes

Several factors contribute to the increased risk of disability in children born prematurely. The immaturity of the brain and other organs at birth can lead to lasting neurological damage. Preterm infants are more likely to experience complications such as respiratory distress syndrome and intraventricular hemorrhage, which can further impact development. Diabetes, both type 1 and type 2, as well as gestational diabetes and obesity, are known risk factors for preterm birth . The study also emphasized the importance of considering social determinants of health, as disparities in access to care and resources can exacerbate the challenges faced by preterm infants and their families.

The Importance of Early Intervention

Early intervention programs play a crucial role in mitigating the long-term effects of preterm birth. These programs provide a range of services, including physical therapy, occupational therapy, speech therapy, and educational support, tailored to the individual needs of each child. The American Academy of Pediatrics (AAP) has developed a framework for monitoring preterm infants to identify developmental risks early on . Regular developmental screenings and timely intervention can help children reach their full potential and minimize the impact of prematurity on their lives. The goal is to provide support and resources to families to help them navigate the challenges of raising a child born prematurely.

Looking Ahead: Continued Research and Support

Further research is needed to better understand the complex interplay of factors that contribute to neurodevelopmental disabilities in children born prematurely. Identifying modifiable risk factors and developing more effective interventions are critical priorities. Continued investment in neonatal care, early intervention programs, and family support services is essential to improve the long-term outcomes for preterm infants. The consequences of prematurity and low birth weight may continue into adulthood, increasing the risk of adult onset chronic conditions such as obesity and diabetes .

This research serves as a vital reminder of the enduring impact of preterm birth and the importance of providing comprehensive, lifelong support to these children and their families. Share your thoughts and experiences in the comments below.

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.